Spineway Future Growth

Future criteria checks 1/6

Spineway is forecast to grow earnings and revenue by 108.1% and 12.3% per annum respectively.

Key information

108.1%

Earnings growth rate

n/a

EPS growth rate

Medical Equipment earnings growth15.9%
Revenue growth rate12.3%
Future return on equityn/a
Analyst coverage

Low

Last updated24 Sep 2024

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

DB:37S - Analysts future estimates and past financials data (EUR Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202616N/AN/A11
12/31/2025150N/A11
12/31/202413-2N/A-11
12/31/202311-7-6-6N/A
9/30/202311-5-11-4N/A
6/30/202311-4-15-3N/A
3/31/202310-4-14-2N/A
12/31/20229-3-14-2N/A
9/30/20227-2-8-2N/A
6/30/20226-2-3-2N/A
3/31/20226-2-3-2N/A
12/31/20215-2-3-2N/A
9/30/20215-2-3-1N/A
6/30/20215-3-2-1N/A
3/31/20215-8-2-1N/A
12/31/20205-14-10N/A
9/30/20205-14-30N/A
6/30/20205-13-40N/A
3/31/20205-8-5-1N/A
12/31/20196-3-6-1N/A
9/30/20196-3-6-2N/A
6/30/20196-4-5-3N/A
3/31/20196-4-5-3N/A
12/31/20187-4-4-3N/A
9/30/20187-4-4-3N/A
6/30/20187-4-3-2N/A
3/31/20188-2-2-1N/A
12/31/201710-1-2-1N/A
9/30/20179-1N/A-1N/A
6/30/20179-1N/A-1N/A
3/31/20177-2N/A-1N/A
12/31/20165-3N/A0N/A
9/30/20165-2N/AN/AN/A
6/30/20166-2N/A0N/A
3/31/20166-2N/A0N/A
12/31/20156-2N/A0N/A
9/30/20156-2N/AN/AN/A
6/30/20155-2N/A-1N/A
3/31/20155-2N/A-1N/A
12/31/20145-2N/A-2N/A
9/30/20146-1N/AN/AN/A
6/30/201460N/A-2N/A
3/31/201460N/A-1N/A
12/31/201370N/A-1N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 37S is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 37S is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 37S is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 37S's revenue (12.3% per year) is forecast to grow faster than the German market (5.4% per year).

High Growth Revenue: 37S's revenue (12.3% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if 37S's Return on Equity is forecast to be high in 3 years time


Discover growth companies